Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$56.27 - $73.77 $41,358 - $54,220
-735 Reduced 14.94%
4,185 $289,000
Q4 2023

Feb 14, 2024

SELL
$59.06 - $75.72 $8,740 - $11,206
-148 Reduced 2.92%
4,920 $363,000
Q3 2023

Nov 13, 2023

BUY
$65.94 - $99.04 $20,705 - $31,098
314 Added 6.6%
5,068 $345,000
Q2 2023

Aug 14, 2023

BUY
$62.68 - $95.05 $297,980 - $451,867
4,754 New
4,754 $446,000
Q4 2017

Jan 25, 2018

SELL
$46.49 - $60.51 $216,039 - $281,189
-4,647 Closed
0 $0
Q3 2017

Oct 03, 2017

BUY
$37.05 - $47.12 $172,171 - $218,966
4,647
4,647 $219,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $12.1B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Eqis Capital Management, Inc. Portfolio

Follow Eqis Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eqis Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Eqis Capital Management, Inc. with notifications on news.